Founded in 2012, InnoSer is an innovative and dynamic contract research organization (CRO) that supports the discovery and preclinical development of drugs. InnoSer’s offerings include a unique, conditional knockout model for ADPKD (nephrology) in mice, a patient derived screening-platform for oncology: PDX/O, and a first-in-class, validated, midbrain-organoid platform to screen drugs for Parkinson’s disease. Also, InnoSer provides pathology- and in-vivo research services including colony management, cryopreservation, sanitation/rederivation.